HilleVax, Inc. (NASDAQ:HLVX) Director Aditya Kohli Sells 723 Shares

HilleVax, Inc. (NASDAQ:HLVX) Director Aditya Kohli sold 723 shares of the business’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $14.15, for a total value of $10,230.45. Following the completion of the transaction, the director now directly owns 782,878 shares of the company’s stock, valued at $11,077,723.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Aditya Kohli also recently made the following trade(s):

• On Wednesday, May 1st, Aditya Kohli sold 175 shares of HilleVax stock. The stock was sold at an average price of $14.03, for a total value of $2,455.25.
• On Friday, April 5th, Aditya Kohli sold 6,000 shares of HilleVax stock. The stock was sold at an average price of $14.44, for a total value of $86,640.00.
• On Wednesday, April 3rd, Aditya Kohli sold 6,000 shares of HilleVax stock. The stock was sold at an average price of $14.93, for a total value of $89,580.00.
• On Wednesday, March 20th, Aditya Kohli sold 6,000 shares of HilleVax stock. The stock was sold at an average price of $164,221.00, for a total value of $985,326,000.00.
• On Monday, March 18th, Aditya Kohli sold 6,000 shares of HilleVax stock. The shares were sold at an average price of $17.66, for a total value of $105,960.00.
• On Friday, March 8th, Aditya Kohli sold 6,000 shares of HilleVax stock. The shares were sold at an average price of $18.66, for a total value of $111,960.00.
• On Wednesday, March 6th, Aditya Kohli sold 6,000 shares of HilleVax stock. The shares were sold at an average price of $18.95, for a total value of $113,700.00.
• On Thursday, February 22nd, Aditya Kohli sold 6,000 shares of HilleVax stock. The shares were sold at an average price of $15.05, for a total value of $90,300.00.
• On Tuesday, February 20th, Aditya Kohli sold 6,000 shares of HilleVax stock. The shares were sold at an average price of $14.88, for a total value of $89,280.00.
• On Monday, February 12th, Aditya Kohli sold 6,000 shares of HilleVax stock. The shares were sold at an average price of $15.32, for a total value of $91,920.00.

HilleVax Trading Down 2.9 %

Shares of NASDAQ HLVX opened at $13.61 on Friday. HilleVax, Inc. has a 1-year low of $9.94 and a 1-year high of $20.22. The business has a 50-day moving average of $15.62 and a 200-day moving average of $14.66. The company has a quick ratio of 10.62, a current ratio of 10.62 and a debt-to-equity ratio of 0.10.

HilleVax (NASDAQ:HLVX) last issued its earnings results on Wednesday, March 20th. The company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.02. As a group, equities analysts anticipate that HilleVax, Inc. will post -3.22 EPS for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $28.00 price target on shares of HilleVax in a research report on Thursday, March 21st.

Institutional Investors Weigh In On HilleVax

Several institutional investors and hedge funds have recently modified their holdings of HLVX. Federated Hermes Inc. lifted its stake in shares of HilleVax by 80.6% in the third quarter. Federated Hermes Inc. now owns 2,113 shares of the company’s stock worth $28,000 after acquiring an additional 943 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of HilleVax in the fourth quarter worth about $139,000. Seven Grand Managers LLC acquired a new position in shares of HilleVax in the third quarter worth about $200,000. Swiss National Bank raised its position in shares of HilleVax by 47.2% during the 3rd quarter. Swiss National Bank now owns 31,200 shares of the company’s stock worth $420,000 after purchasing an additional 10,000 shares during the period. Finally, abrdn plc acquired a new stake in shares of HilleVax during the 4th quarter worth approximately $433,000. Hedge funds and other institutional investors own 86.42% of the company’s stock.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.